News Datroway joins Trodelvy for frontline TNBC in the EU AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
Oncology ASCO 2026: Three ADC approvals in five days, with Ken Keller... At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
News Datroway is first TROP2 drug for frontline breast cancer AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.
News Manufacturing hangover drives Daiichi Sankyo into the red Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.
News Daiichi exits OTC, with $1.55bn unit sale to Suntory Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.
News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.